Fed Circ. upholds some Teva migraine drug patents, invalidates others | Reuters
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
Teva's migraine drug Ajovy looks set for EU approval -
Teva tackles migraine through potential $400m Heptares collaboration
Teva Pharmaceutical Industries Ltd. - New research by Teva has thrown a spotlight on how badly affected women are by #migraine. But behind those numbers are real people. Come and meet some
Teva Pharmaceuticals on Twitter: "Meet our #migraine expert, Dr Joshua Cohen, as he shares his own story of living with #migraine and explains the impact the disease can have on patients. Read
Teva's migraine med given marketing authorization
Teva - Migraine World Summit
Teva tries to make something out of nothing with Ajovy approval | Evaluate
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire
Teva stops selling migraine patch after reports of burns
FDA approves Teva's migraine injection AJOVY™ - Pf Media
Teva Halts Phase III Trial of Fremanezumab in Chronic Cluster Headaches
Teva's recalled migraine medicine Zecuity has a long local history - Philadelphia Business Journal
FDA approves Vyepti, first IV preventive treatment for migraine
Ajovy, Teva's migraine drug, recommended by UK's NICE.
Ajovy™ Approved by FDA for Migraine Prevention in Adults
Teva scraps Heptares migraine pact as lead drug nears clinic | Fierce Biotech
No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma
Teva migraine treatment approved by FDA - Philadelphia Business Journal
Preventive Treatment of Migraine–AJOVY® (fremanezumab-vfrm) injection
Eli Lilly (NYSE:LLY) Loses Migraine Drug Patent Trial to Teva
Teva discontinues trial of Ajovy for episodic cluster headache - Pharmaceutical Technology
Teva v. Eli Lilly: Teva argues Lilly is infringing migraine drug patent in the United States - Harvard Journal of Law & Technology
Eli Lilly avoids sanctions in Teva migraine treatment dispute
Boston Jury Awards Teva Pharmaceuticals $176.5M for Eli Lilly's Migraine Medication Patent Infringement | Law.com
